MindMaze Therapeutics has appointed Dr John Krakauer as a strategic advisor to support its next phase of growth in the United States. “John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery,” said Zach Henderson, CEO of MindMaze Therapeutics. “As… Read More
Calla Lily Clinical Care, a women’s health-focused medical technology company, has joined Wellcome Leap’s Focused Antibiotics programme – a new $50m funded programme to transform how antibiotics are delivered and address the growing global threat of antimicrobial resistance (AMR). Founded by the Wellcome Trust in 2020, US non-profit Wellcome Leap… Read More
CDMO Cambrex has begun construction on a new R&D facility in Milan, Italy, a $30 million investment will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants. The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future… Read More
Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More
Investment in rare disease biotechs has increased following renewal of the FDA’s Priority Review Voucher (PRV) programme, according to SynaptixBio, but the United States remains dominant compared to the UK. In February 2026, the PRV programme was signed into law and will remain in place until reviewed again in September… Read More
Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, has launched BaseMap ABE. Built on the company’s INDUCE-seq technology, BaseMap ABE extends the platform’s capabilities to support adenine base editing (ABE) applications. Base editing is rapidly gaining momentum as a… Read More
Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, has closed a new financing round exceeding $31 million (over RMB 200 million). The round was led by Guozhong Capital, with participation from IDG Capital, China Everbright Limited, Jolmo Capital, Win-Win Capital, and SND Financial… Read More
Basking Biosciences, a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy for acute ischemic stroke (AIS), has announced the publication of preclinical research in Communications Biology, a Nature Portfolio journal. The study shows that its lead candidate, BB-031, restores blood flow in a microfluidic model of arterial occlusion… Read More
News round-up for 27-31 July by Megan Thomas, Content Team at DDW. This week’s news roundup centres around investment, innovation and strategic growth, which have dominated this week’s headlines. Across the drug discovery sector, companies have secured funding, expanded R&D capabilities and accelerated the adoption of AI-driven… Read More
The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May. HTX-001 is a… Read More
An unexpected observation by a University of Queensland (UQ) researcher could lead to a new treatment for deadly infectious diseases including Covid‑19, pneumonia in infants and children, or viral infections caused by Ebola and hantavirus. UQ’s Australian Institute for Bioengineering and Nanotechnology neuroscientist and biochemist Dr… Read More
Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases. Existing investors Hargreave Hale… Read More
We are pleased to announce the preliminary speaker lineup for the Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place 30 September 2026. Supported by DDW, the forum brings together senior leaders from biotech, pharma, academia, and investment to explore the opportunities and challenges shaping early-stage drug discovery. Running… Read More
AnHorn Medicines has dosed the first subject in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This milestone marks the clinical advancement of a novel therapeutic approach designed to address one of the most common and debilitating complications of… Read More
In a report published on July 16 2026, titled Lab-in-the-Loop: AI Rewires Antibody Discovery, Unlocking a US$7 billion LST Opportunity, “Lab-in-the-Loop” (LitL) is described as an emerging approach in which AI models propose candidate antibody sequences, wet lab experiments test them, and the resulting data is fed back into the… Read More
Chris McDonald has been appointed the UK’s new science minister following the resignation of Patrick Vallance. McDonald, who became a Minister of State at the newly formed Department for Business, Innovation, Science and Trade (Dbist) on 21 July, also took up a role at the Department of Health and Social… Read More
